Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IRX 5183

Drug Profile

IRX 5183

Alternative Names: AGN 195183; IRX5183; NRX 195183; VTP-195183

Latest Information Update: 13 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer Io Therapeutics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Antipsoriatics
  • Mechanism of Action Immunostimulants; Retinoic acid receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer
  • Phase I Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Discontinued Psoriasis; Stem cell mobilisation

Most Recent Events

  • 13 May 2019 Discontinued - Clinical-Phase-Unknown for Psoriasis in USA (PO)
  • 18 Apr 2019 Io Therapeutics terminates a phase I trial in Acute myeloid leukaemia, Myelodysplastic syndromes and Chronic myelomonocytic leukaemia (Second-line therapy or greater) in USA as the study drug supply expired and could not be renewed (PO) (NCT02749708)
  • 14 May 2016 Phase-I/II development for Cancer is ongoing in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top